Ein Milliarden Dollar Unternehmen wurde geboren?


Seite 4 von 6
Neuester Beitrag: 02.01.13 16:28
Eröffnet am:06.11.12 08:26von: sauerland150.Anzahl Beiträge:138
Neuester Beitrag:02.01.13 16:28von: wamu2009Leser gesamt:21.130
Forum:Hot-Stocks Leser heute:3
Bewertet mit:
3


 
Seite: < 1 | 2 | 3 |
| 5 | 6 >  

881 Postings, 5016 Tage sauerland15026 Monate keinen neuen Shares!

 
  
    #76
15.11.12 09:51
AMBS-Amarantus BioSciences Secures $1.1 Million in Financing

MAJOR NEWS RELEASED NEAR END OF BELL!

Wed Nov 14, 1:53PM CST

SUNNYVALE, Calif. , Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.

"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong , President and CEO of Amarantus. "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."

Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000 . The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.

Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.  

45 Postings, 5196 Tage baembidas....

 
  
    #77
1
15.11.12 09:58
rauscht heute noch weiter runder.....schaut  mal wo die aktie herkam  

190 Postings, 4703 Tage Filbiremushi baembi...

 
  
    #78
1
15.11.12 10:40
Ich glaube nicht das es noch weiter runter geht, sonst hätte der investor doch nicht für das stk 0,10 bezahlt.
Warten wir mal ab was da noch kommt die nächten tage.  

341 Postings, 4489 Tage Jotteaber filbiremus

 
  
    #79
15.11.12 10:56
das sind ja 0,10$ nicht Euro, in euro sind das derzeit 0,07€
ich bin sher gespannt, wie es weitergeht...  

1427 Postings, 6846 Tage killercopbei 0,006

 
  
    #80
1
15.11.12 11:01
steige ich ein  

881 Postings, 5016 Tage sauerland1502News!

 
  
    #81
15.11.12 12:50

881 Postings, 5016 Tage sauerland1502News!

 
  
    #82
15.11.12 12:50
Amarantus BioSciences Secures $1.1 Million in Financing


Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Amarantus BioSciences, Inc.

Convertible Note investment into the Company priced at $0.10 per share

SUNNYVALE, Calif., Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions.  Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital. 

"Amarantus is at a pivotal stage in our corporate development, and these transactions provide us with capital to advance our research collaborations, continue our efforts to progress MANF into clinical trials, as well as strengthen the Company's balance sheet, making the Company more attractive to the investment community," said Gerald E. Commissiong, President and CEO of Amarantus.  "Interim data for MANF showed promising results in behavioural animal models of Parkinson's disease, and we expect final data to be available in December. With this financing, the Company can make more substantial progress with our product candidates, allowing management to market the MANF opportunity to potential partners as well as look at creative financing structures to ensure MANF and NuroPro's further development. We remain focused on moving our Parkinson's assets towards clinical trials to explore the potential benefits for patients, and we will also begin to explore additional applications for the MANF technology which may address larger markets, and/or address smaller orphan drug markets that have more rapid paths to commercialization."

Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000. The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions.  The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.

Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion.  The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

Amarantus BioSciences, Inc.
(408) 737-2734
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com  

45 Postings, 5196 Tage baembiKönnte heute explodieren...

 
  
    #83
1
15.11.12 13:00

69 Postings, 4680 Tage Deidarawird

 
  
    #84
15.11.12 13:02
in berlin weitergehandelt oder gibt es wie in frankfurt auch delistings zum 15.12.?
wenn ja, ist amarantus betroffen?  

341 Postings, 4489 Tage Jotteja baembi...

 
  
    #85
2
15.11.12 13:06
was denn nun, erst schreibst du "rauscht heute runter" (09:58 / #77) und jetzt auf einmal "könnte heute explodieren"? Du musst dich schon mal festlegen, sonst wird´s ein bischen unglaubwürdig! ;-)  

190 Postings, 4703 Tage FilbiremusEin Satz mit X - Das war wohl nix!

 
  
    #86
15.11.12 15:46
Bei 0,006 einzusteigen, versuche es halt mal bei 0,06:-)  

1427 Postings, 6846 Tage killercopWarum 0,06 bezahlen

 
  
    #87
15.11.12 18:58
wenn ich se für weniger bekommen werde....
warten wirs ab...hihi  

341 Postings, 4489 Tage Jottesagt mal...

 
  
    #88
19.11.12 11:42
hier passiert auch nix mehr, ausser das der Kurs runter geht!  

1056 Postings, 5409 Tage wamu2009@ all

 
  
    #90
19.11.12 15:45
NOKOMIS, Fla., Nov 19, 2012 (BUSINESS WIRE) -- As Rainbow Coral Corp. looks ahead to a successful 2013, the company has placed a high priority on initiating projects that will realize profits quickly.

The first project to be fast-tracked will be the company's joint venture with Amarantus BioSciences (OTCBB: AMBS). Both companies forswear realizing revenues from the impending commercialization of Amarantus' NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson's disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.

RBCC and Amarantus expect to finalize NuroPro's development timeline within the next 12-14 months. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal.

The shortened timeline became a possibility last week when Amarantus secured over $1.1 million in funding through two separate transactions. RBCC plans to invest in the ongoing development of NuroPro and to be repaid for its investment out of proceeds from the sales generated by the revolutionary diagnostic blood test.

If milestones are met, RBCC will then share in its revenues sooner than originally anticipated, once the initial investment is repaid.

For more information on Rainbow BioSciences' neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

SOURCE: Rainbow BioSciences, LLC

CONTACT:          

Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO info@rainbowcoral.com

Copyright Business Wire 2012  

341 Postings, 4489 Tage Jottetrotz der gewonnenen

 
  
    #92
21.11.12 11:06
Patentschlacht geht es jetzt aber runter... ;-(
Was meint ihr, wo geht es noch hin?  

341 Postings, 4489 Tage Jottealso ich glaube

 
  
    #93
1
22.11.12 08:22
der Thread sollte eher "ein Milliardengrab" heissen ;-)  

1427 Postings, 6846 Tage killercopbei 0,006 geh ich mal rein

 
  
    #94
26.11.12 12:50

45 Postings, 5196 Tage baembiNews

 
  
    #95
29.11.12 14:00
RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit

NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) nears a new joint venture agreement to commercialize advances made by Amarantus BioSciences (OTCBB: AMBS), the company’s latest target continues to seek out additional investment capital from high-profile investors.

   “We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike”

Amarantus Chief Science Officer John W. Commissiong recently presented his organization’s brilliant MANF therapeutic protein for Parkinson’s disease at the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings together researchers, developers and investors to collaborate in bringing new treatments to patients suffering from brain disorders.

The high-profile event put Amarantus’ proprietary, anti-apoptosis therapeutic protein in the spotlight in front of researchers and investors from around the world.

“We continue to be very impressed with Amarantus’ outreach efforts toward potential investors and clients alike,” said RBCC CEO Patrick Brown. “We look forward to wrapping up our joint venture agreement shortly, and then our first priority will be moving their groundbreaking therapeutics forward toward full commercialization.”

Both companies forswear realizing revenues from the impending commercialization of Amarantus’ NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson’s disease. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal. Next in line for commercialization will be MANF.

For more information on Rainbow BioSciences’ neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com  

881 Postings, 5016 Tage sauerland1502News

 
  
    #96
04.12.12 11:03
AMBS mentioned in Seeking Alpha Article (big boards)!!

Seems like the news says the company hasn't sold any shares since the 10Q got released. I've been waiting quiet to get in again today.

Been playing ACAD (big board) and saw a seeking alpha article mentioning AMBS. Don't see seeking alpha posting stuff abt penny stocks that much but when it does, it does generate buzzzzZZZ

http://seekingalpha.com/article/...-focus-to-parkinson-s?source=yahoo

About AMBS:

Quote:
Amarantus Bioscience (AMBS.OB)is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.


Quote:
The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, the company announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug.


About Parkinson's disease:

Quote:
Parkinson's disease psychosis is a debilitating disorder that develops in up to 60% of patients with Parkinson's disease. Currently, there is no FDA-approved therapy to treat PDP in the United States.  

881 Postings, 5016 Tage sauerland1502aus dem Nachbarboard:

 
  
    #97
04.12.12 11:09
LEUTE WICHTIGE NACHRICHT IST RAUS!

KEINE DILUTION!
SEIT DER Q10 DIE AKTIENANZAHL NICHT GEÄNDERT!

WEDER MANAGEMENT NOCH OFFICERS HABEN AKTIEN VERKAUFT!

KEINER HAT AKTIEN VERÄUSSERT!

SOMIT SIND ALLE DIE DILUTION, PUMP & DUMP, VERAR**SCHE GESCHRIEN HABEN EIN FÜR ALLE MAL STUMM!

"The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals."

SUNNYVALE, Calif., Dec. 3, 2012

http://ih.advfn.com/p.php?pid=nmona&article=55291531

--------------------------------------------------

SOGAR ICH HABE DER FIRMA DERART ÜBLES LEISE UNTERSTELLT; DASS SIE EINEN HYPE LOSGELÖST HABEN UND AKTIEN VERHÖCKERN!

NACH WIE VOR SIE HABEN IM SINNE DER AKTIONÄRE GEHANDELT UND CONVERTIBLES FÜR 0,10 0,11 0,16 bis 0,20 VERGEBEN!

gute nacht leute, das sind sehr gute neuigkeiten! sollte den letzten zweifel wegräumen, und brauchen nicht den chart starren! der enge kreis hier weiss jetzt eigentlich ganz genau wo wir in paar monaten stehen werden. lasst euch von dummschwätzern auch nichts einreden,
auch im usbord standen ja die "longs" auch wie trottel da,die longs wären opfer von pump & dump, der ceo würde uns abzocken die firma würde dilutieren usw...jemand der kein mitgefühl und taktgefühl hat der hat nur ein axelzucken verdient, dieser knappe statement zeigt wo die firma steht und es nicht nötig hat mit fiesen tricks de aktionäre abzuzocken.

gute nacht bambi jotte herr lüdenscheidt timm hugedubel sundancer filbiremus thyr und alle anderen, haltet besser eure aktien fest, nichts ist verloren, und Larry bei Dir heisst es genau beobachten. vielleicht wie gesagt waren die 0,02 (für mich) und 0,018 für paar für euch weinachtsgeschenke der besonderen art.und danke an die basher! ;)  

881 Postings, 5016 Tage sauerland1502Wir sind wieder auf Kurs!

 
  
    #98
04.12.12 15:59

881 Postings, 5016 Tage sauerland1502Für 0,015 € in Berlin verkauft, dafür hätte ich

 
  
    #99
04.12.12 16:08
auch noch aufgestockt!  

881 Postings, 5016 Tage sauerland1502Gleich ist grillen angesagt!

 
  
    #100
04.12.12 16:10

Seite: < 1 | 2 | 3 |
| 5 | 6 >  
   Antwort einfügen - nach oben